Novartis AG (NVS)
- Previous Close
92.57 - Open
93.20 - Bid --
- Ask --
- Day's Range
93.15 - 94.50 - 52 Week Range
92.19 - 108.78 - Volume
2,319,648 - Avg. Volume
1,511,985 - Market Cap (intraday)
192.875B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
23.01 - EPS (TTM)
4.10 - Earnings Date --
- Forward Dividend & Yield 3.78 (4.00%)
- Ex-Dividend Date Mar 7, 2024
- 1y Target Est
113.76
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
www.novartis.com76,057
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NVS
Performance Overview: NVS
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVS
Valuation Measures
Market Cap
191.59B
Enterprise Value
203.97B
Trailing P/E
23.01
Forward P/E
13.35
PEG Ratio (5yr expected)
5.14
Price/Sales (ttm)
4.23
Price/Book (mrq)
4.13
Enterprise Value/Revenue
4.37
Enterprise Value/EBITDA
11.17
Financial Highlights
Profitability and Income Statement
Profit Margin
31.83%
Return on Assets (ttm)
7.27%
Return on Equity (ttm)
16.15%
Revenue (ttm)
46.66B
Net Income Avi to Common (ttm)
8.57B
Diluted EPS (ttm)
4.10
Balance Sheet and Cash Flow
Total Cash (mrq)
14.07B
Total Debt/Equity (mrq)
56.55%
Levered Free Cash Flow (ttm)
12.13B
Research Analysis: NVS
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: NVS
Analyst Report: Novartis AG
Novartis is a pharmaceutical company based in Switzerland. Its portfolio is focused primarily on the areas of Immunology, Neuroscience, Oncology, Cardiovascular, Renal, and Metabolic therapies. The company employs more than 78,000 people and its medicines reach more than 280 million people worldwide.
RatingNeutralPrice TargetMarket Update: NVS, BYD, CVX, DE, ITGR, CBOE, FTV
Stocks are trading lower on Tuesday morning on some weaker-than-expected economic data as well as growing concerns that AI-related stocks are overbought at this juncture. Specifically, the Conference Board's Leading Economic Index slipped 0.4% in January and was lower than the expected 0.3% drop. The index was down 3.0% over the past six months -- a narrower decline than the preceding six-month period, which fell by 4.1%. Still, with six of the 10 index components being positive over the past six-month period, the index no longer is signaling a recession ahead. Turning to stocks, shares of Nvidia (NVDA) are down today, with the company reporting earnings tomorrow after market close. Despite expectations for positive earnings results, the selloff indicates many investors may be concerned that the shares are due for a pullback following an impressive run this year (which saw shares rise over 50% to an all-time high set last week). Shares of other tech companies which also saw strong gains related to AI prospects are trading lower on overvaluation concerns, including Arm Holdings (ARM), Advanced Micro Devices (AMD), and Super Micro Computer (SMCI).
Analyst Report: Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
RatingNeutralPrice TargetAnalyst Report: Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
RatingNeutralPrice Target